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Background:  Statins  have  been  reported  to  reduce  cardiovascular  events  in  patients  with  coro-
nary artery  disease  (CAD).  Percutaneous  coronary  intervention  (PCI)  is  commonly  used  to  relieve
ischemic symptoms  in  patients  with  CAD.  However,  there  is  little  information  on  the  effect  of
statins on  cardiovascular  events  after  PCI,  even  in  the  era  of  coronary  stent  implantation.
Methods:  A  total  of  1019  patients  with  acute  or  chronic  CAD  and  modest  total  cholesterol  levels
(180—240  mg/dl)  were  enrolled  and  randomly  assigned  to  treatment  with  or  without  statins.
We evaluated  the  effect  of  any  available  statin  on  the  incidence  of  cardiovascular  events  after
PCI. The  primary  endpoint  was  a  composite  of  cardiovascular  death,  nonfatal  acute  myocardial
infarction  (MI),  recurrent  angina  pectoris  requiring  emergency  rehospitalization  (rAP),  heart
failure, and  stroke.
Results:  Indications  for  PCI  were  stable  angina  in  54%,  ST-elevation  MI  in  41%  and  non-ST-
elevation MI/unstable  angina  pectoris  in  5%.  After  2  years  of  statin  treatment,  low-density
lipoprotein  cholesterol  (LDL-C)  decreased  from  133  to  96  mg/dl.  Stents  were  implanted  in  84%
of all  cases.  The  primary  endpoint  event  rate  was  9.5%  in  the  statin  group  and  14.7%  in  the  non-
statin group  (p  =  0.0292).  Of  all  primary  endpoint  events,  only  rAP  was  signiﬁcantly  suppressed
by statins  (p  =  0.0027).  In  rAP  patients,  coronary  angiography  revealed  that  statins  suppressed
restenosis but  not  new  lesions.
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Conclusions:  For  Japanese  CAD  patients  treated  with  PCI  and  stent  implantation,  statin  ther-
apy reduced  the  incidence  of  recurrent  cardiovascular  events,  particularly  rAP.  Discretionary












































symptomatic  myocardial  ischemia  with  objective  evidence
[recurrent  angina  pectoris  (rAP)],  congestive  heart  fail-
ure  (CHF)  that  required  emergent  rehospitalization,  andrAP.
© 2011  Japanese  College  of  C
Introduction
Treatment  of  patients  with  coronary  artery  disease  (CAD)
with  3-hydroxy-3-methylglutaryl  coenzyme  A  reductase
inhibitors  (statins)  has  been  reported  to  decrease  the
incidence  of  cardiovascular  events  [1—3]. Furthermore,
percutaneous  coronary  intervention  (PCI)  is  commonly  per-
formed  to  relieve  ischemic  symptoms  in  patients  with
CAD.  Recently,  it  has  been  reported  that  optimal  medical
therapy  with  or  without  PCI  is  equally  effective  in  pre-
venting  cardiovascular  events  [4].  Optimal  medical  therapy
includes  aspirin,  -blockers,  angiotensin-converting  enzyme
inhibitors,  statins,  and  other  agents.  Thus,  PCI  may  be
less  important  than  optimal  medical  therapy  in  reducing
future  cardiovascular  events  in  patients  with  CAD.  In  fact,  in
the  Lescol  Intervention  Prevention  Study  (LIPS),  ﬂuvastatin
reduced  the  risk  of  major  adverse  cardiovascular  events
(MACE)  signiﬁcantly  in  patients  undergoing  their  ﬁrst  suc-
cessful  PCI  [5].  However,  extrapolation  of  these  results  to
Japanese  patients  who  have  undergone  PCI  is  uncertain,
because  the  Japanese  population  has  a  lower  mortality  from
coronary  artery  disease  compared  with  Western  populations
[6].
In  the  present  multicenter,  randomized,  controlled  trial,
we  investigated  the  effects  of  statins  on  cardiovascular
events  in  Japanese  patients  with  acute  or  chronic  ischemic
heart  disease  who  underwent  PCI  with  stents.  In  addition,
we  used  coronary  angiography  (CAG)  to  precisely  identify
the  culprit  lesions  in  patients  who  required  emergent  rehos-
pitalization  for  recurrent  myocardial  ischemia.
Methods
Study  population
Between  February  2002  and  September  2004,  1019  con-
secutive  patients  were  enrolled  at  55  medical  centers  in
19  prefectures  of  Japan  (see  Appendix  A).  The  patients
had  acute  or  chronic  myocardial  ischemia  and  serum  total
cholesterol  levels  ranging  from  180  to  240  mg/dl  on  admis-
sion.  All  were  to  undergo  emergent  or  elective  (including
ad  hoc)  PCI  for  their  myocardial  ischemia  if  CAG  showed
that  their  coronary  lesions  were  suitable  for  PCI.  Main  exclu-
sion  criteria  included  <18  years  of  age,  use  of  lipid-lowering
agents  within  the  previous  3  months,  known  familial  dyslipi-
demia,  severe  renal  failure,  known  hepatic  disease,  signs
and  symptoms  of  severe  heart  failure  (New  York  Heart  Asso-
ciation  class  III  or  IV),  a  scheduled  coronary  artery  bypass
grafting  (CABG),  previous  PCI  (within  6  months)  or  CABG
(within  3  months),  and  the  presence  of  malignant  disease  or
allergy  to  statins.  Patients  with  acute  myocardial  ischemia
included  in  the  present  study  comprised  a  large  percent-
age  of  the  population  in  the  MUSASHI-AMI  trial  as  described
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hose  treated  with  thrombolytics  in  the  MUSASHI-AMI  trial
ere  excluded  from  the  present  study.
tudy  design
he  Multicenter  Study  for  Aggressive  Lipid-Lowering  Strat-
gy  by  HMG-CoA  Reductase  Inhibitors  in  patients  with  CAD
MUSASHI)  was  a  PROBE-design  trial  conducted  in  normo-
holesterolemic  patients  who  were  randomly  assigned  to
eceive  any  available  statin  or  no  statin.  The  MUSASHI
tudy  population  consisted  of  MUSAHI-AMI  (acute  myocardial
nfarction)  and  MUSASHI-PCI  (percutaneous  coronary  inter-
ention)  patients.  The  study  was  performed  in  accordance
ith  the  ethical  principles  of  the  Declaration  of  Helsinki  and
as  approved  by  local  ethics  committees  or  institutional
eview  boards.  Written  informed  consent  was  obtained  from
ll  patients.  The  acute  myocardial  infarction  (AMI)  and
nstable  angina  pectoris  (uAP)  patients  who  underwent  PCI
ere  randomly  assigned  within  96  h  after  symptom  onset,
nd  the  stable  angina  patients  were  randomly  assigned
ithin  48  h  after  PCI  with  stratiﬁcation  by  center  using  the
nvelope  method  to  standard  medical  treatment  with  or
ithout  the  addition  of  a  statin.
The  beneﬁts  of  statin  therapy  were  not  well  established
t  that  time  in  Japan.  The  statin  treatment  was  open  label
ith  any  statin  that  was  available  in  Japan  during  the
ecruitment  period  (pravastatin,  atorvastatin,  ﬂuvastatin,
imvastatin,  or  pitavastatin).  Patients  were  monitored  for  a
rimary  endpoint  event  every  30  days  at  each  institutional
utpatient  clinic  for  up  to  2  years.  All  patients  received
nstruction  and  counseling  to  promote  compliance  with  the
apan  Atherosclerosis  Society  Guidelines  for  Diagnosis  and
reatment  of  Atherosclerotic  Cardiovascular  Diseases  Step  I
iet  [8].  During  follow-up,  emergent  CAG  was  performed  in
ase  of  recurrent  myocardial  ischemia  including  AMI.  Even  if
mergent  CAG  was  not  required,  routine  CAG  was  scheduled
—6  months  after  enrollment  regardless  of  ischemic  symp-
oms  to  evaluate  changes  in  the  culprit  lesion  and  lesions  at
ther  sites.  According  to  the  results  of  follow-up  coronary
ngiography,  CABG  or  PCI  was  performed  for  a  new  lesion  or
estenosis  of  a  previous  lesion,  if  necessary.
ndpoint  events
he  primary  endpoint  event  was  deﬁned  as  a  combina-
ion  of  cardiovascular  death,  nonfatal  acute  myocardial
nfarction  (MI),  emergent  rehospitalization  due  to  recurrentonfatal  stroke.  In  cases  of  AMI  and  rAP,  emergent  or
ub-emergent  CAG  was  performed,  and  culprit  lesions  for
cute  myocardial  ischemia  were  examined  and  treated  by
epeat  PCI  or  coronary  artery  bypass  grafting,  if  necessary.
210  R.  Tsunoda  et  al.
Table  1  Baseline  characteristics  of  the  patients.
Characteristic  Statin  group
(n  =  504)
Non-statin
group  (n  =  515)
p-Value
Age,  mean  (SD)  (years)  64.8  (10.5)  66.4  (10.5)  0.0131
Male, n  (%)  385  (76)  393  (76)  0.9766
BMI, mean  (SD)  (kg/m2)  24.2  (10.5)  24.1  (9.1)  0.9053
Hypertension,  n  (%)  326  (65)  311  (60)  0.2380
Current or  ex  smoker,  n  (%) 253  (50)  269  (52)  0.4953
Diabetes, n  (%) 156  (31) 146  (28)  0.3732
Previous MI,  n  (%) 68(13) 71  (14) 0.8327
Previous stroke,  n  (%) 40  (8) 48  (9) 0.4317
Previous PCI,  n  (%) 77  (15) 72  (14) 0.5753
Concomitant  medications,  n  (%)
Aspirin  485  (96)  481  (93)  0.0581
-blockers 112  (22)  114  (22)  0.9736
Ca++ channel  blockers  237  (47)  245  (48)  0.8607
Nitrates 154  (31)  192  (37)  0.0234
ACE inhibitors  175  (35)  154  (30)  0.1145
ARBs 179  (36)  190  (37)  0.6474
Lipids, mean  (SD)  (mg/dl)
Total  cholesterol  208  (17)  206  (17)  0.0146
LDL-cholesterol  133  (22)  130  (20)  0.0768
HDL-cholesterol  47  (13)  47  (12)  0.2686
Triglycerides  144  (90)  142  (77)  0.7682
CRP, mean  (SD)  (mg/L) 4.5  (9.5)  5.5  (12.0)  0.5073




















































pangiotensin II receptor blockers; LDL, low-density lipoprotein; HD
owever,  reintervention  after  routine  CAG  was  not  included
s  a  primary  endpoint  event,  and  follow-up  was  terminated
n  patients  that  required  this  type  of  reintervention.  Car-
iovascular  death  was  deﬁned  as  that  directly  or  indirectly
elated  to  AMI  or  ischemic  heart  disease.  Deﬁnitions  of  AMI
nd  heart  failure  were  the  same  as  previously  reported  [7].
troke  was  diagnosed  based  on  the  presence  of  a  neuro-
ogic  deﬁcit  that  was  conﬁrmed  by  computed  tomography
r  magnetic  resonance  imaging.
tatistical  analysis
ata  are  expressed  as  mean  ±  SD  or  median  (range).  Differ-
nces  in  patient  characteristics  between  the  2  treatment
roups  were  evaluated  with  Student’s  t test  in  the  case  of
ontinuous  variables  and  a  chi-square  test  in  the  case  of
bsolute  categorical  variables.  Data  that  were  not  normally
istributed  were  analyzed  with  a  Wilcoxon’s  2-sample  test.
umulative  event  curves  of  the  study  endpoint  (the  time
rom  PCI  to  a  speciﬁed  event  in  each  patient)  were  plot-
ed  with  the  Kaplan—Meier  method  and  differences  between
vent  curves  were  compared  with  a  log-rank  test.  Estimates
f  hazard  ratios  and  associated  95%  conﬁdence  intervals
hat  compared  the  two  groups  were  obtained  with  a  Cox
roportional  hazards  model.  Interim  statistical  analyses  of
he  study  outcome  were  performed  for  independent  data.  A
-value  <0.05  was  considered  statistically  signiﬁcant.  All  sta-
istical  analyses  were  conducted  with  SAS  8.2  (SAS  Institute,




oh-density lipoprotein; CRP, C-reactive protein.
esults
atients
etween  February  2002  and  September  2004,  1019  patients
ere  enrolled;  504  were  assigned  to  receive  standard  ther-
py  with  discretional  statins,  and  515  were  assigned  to
eceive  standard  therapy  without  statins.  Patients  with  fatal
omplications  of  acute  phase  AMI,  such  as  free  wall  rupture,
nd  cases  with  study  protocol  violations  were  withdrawn.
atients  who  could  not  tolerate  statin  side  effects  were  also
xcluded.  The  remaining  482  patients  in  the  statin  group
nd  497  patients  in  the  non-statin  group  were  followed
p  to  2  years.  The  baseline  demographic  characteristics  of
oth  groups  were  similar,  except  for  a  higher  mean  age  in
he  non-statin  group  (64.8  vs.  66.4  years),  more  frequent
dministration  of  nitrates  in  the  non-statin  group  (31%  vs.
7%)  and  a higher  mean  total  cholesterol  level  in  the  statin
roup  (208  ±  17  vs.  206  ±  17  mg/dl)  (Table  1).  PCI  for  sta-
le  angina,  ST-elevation  MI,  and  non-ST-elevation  MI/uAP
as  performed  in  261  (54%),  193  (40%),  and  28  (6%)  patients
n  the  statin  group,  and  269  (54%),  207  (42%),  and  21  (4%)
n  the  non-statin  group,  respectively.  A  coronary  stent  was
mplanted  in  401  patients  (83%)  in  the  statin  group  and  425
86%)  in  the  non-statin  group;  conventional  balloon  angio-
lasty  was  performed  in  81  (17%)  in  the  statin  group  and  72
14%)  in  the  non-statin  group.  There  were  no  signiﬁcant  dif-
erences  in  the  indication  and  type  of  PCI  between  the  two
roups.  Coronary  stent  implantation  was  performed  in  >80%
f  all  patients.  Bare  metal  stents  were  implanted  rather



























vFigure  1  Serial  changes  in  low-density  lipoprotein  cholestero
and non-statin  groups.  *p  <  0.001.  LDL-C,  low-density  lipoprotei
than  drug-eluting  stents  (DES),  because  the  latter  were  not
available  at  that  time  in  Japan.
Statin  therapy  and  changes  in  serum  lipid  levels
The  fraction  of  each  statin  used  in  the  present  study  and
the  mean  daily  dose  were  as  follows:  pravastatin  (49.8%,
9.5  mg),  atorvastatin  (31.1%,  9.4  mg),  ﬂuvastatin  (14.3%,
27.1  mg),  simvastatin  (4.6%,  5.4  mg),  and  pitavastatin  (0.2%,
2.0  mg).  As  mentioned  above,  serum  total  cholesterol  lev-
els  were  higher  in  the  statin  group  at  baseline,  whereas
levels  of  low-density  lipoprotein  cholesterol  (LDL-C)  were
equivalent  in  the  two  groups.  After  2  years  of  treatment,
LDL-C  levels  decreased  28%  in  the  statin  group  and  7%  in
the  non-statin  group  (p  <  0.001  in  both).  There  was  a  signiﬁ-
cant  difference  in  the  LDL-C  levels  between  the  two  groups
from  6  months  after  randomization  to  the  end  of  the  follow-
up  period  (p  <  0.0001).  High-density  lipoprotein  cholesterol
(HDL-C)  levels  were  signiﬁcantly  increased  from  47  mg/dl  to
50  mg/dl  in  the  statin  group  and  47  mg/dl  to  48  mg/dl  in  the
non-statin  group  (p  <  0.01  in  both)  after  2  years.  However,
there  was  no  signiﬁcant  difference  between  the  two  groups
(Fig.  1).Endpoint  events
Kaplan—Meier  cumulative  event  curves  of  the  primary  end-





Figure  2  Kaplan—Meier  cumulative  eveels  and  high-density  lipoprotein  cholesterol  levels  in  the  statin
lesterol;  HDL-C,  high-density  lipoprotein  cholesterol.
n 46  patients  (9.5%)  in  the  statin  group  and  in  73  (14.7%)  in
he  non-statin  group  during  the  follow-up  period  (p  =  0.0292
y  log-rank  test).  The  relative  risk  of  the  primary  endpoint
as  reduced  by  34%  with  statin  treatment  during  a  mean
ollow-up  of  416  ±  11  days.  When  individual  events  were
onsidered  separately,  2  (0.4%)  patients  in  the  statin  group
nd  2  (0.4%)  in  the  non-statin  group  died  from  cardiovascular
auses;  7  (1.5%)  in  the  statin  group  and  3  (0.6%)  in  the  non-
tatin  group  had  a  nonfatal  MI;  23  (4.7%)  in  the  statin  group
nd  51  (10.4%)  in  the  non-statin  group  had  rAP  requiring
mergent  rehospitalization;  7  (1.5%)  in  the  statin  group  and
2  (2.4%)  in  the  non-statin  group  required  emergent  rehospi-
alization  for  CHF;  7  (1.5%)  in  the  statin  group  and  5  (1.0%)
n  the  non-statin  group  had  a  nonfatal  stroke.  In  the  sub-
roup  of  patients  that  had  conventional  balloon  angioplasty,
 primary  endpoint  event  occurred  in  8  patients  (9.9%)  in
he  statin  group  and  in  15  (20.8%)  in  the  non-statin  group.
n  the  stent  subgroup,  a  primary  endpoint  event  occurred  in
8  patients  (9.5%)  in  the  statin  group  and  58  (13.6%)  in  the
on-statin  group.  The  relative  risk  reduction  of  the  primary
ndpoint  in  the  stent  subgroup  (30.1%)  was  signiﬁcantly
ower  than  that  in  the  conventional  balloon  angioplasty  sub-
roup  (52.4%).  When  individual  endpoints  were  analyzed
eparately,  the  statin  group  had  a  lower  risk  of  rAP  (4.8%
s.  10.4%,  p  =  0.0027),  whereas  the  risk  of  the  other  end-
oints  was  comparable  between  the  two  groups  (Fig.  3).
ngiographic  analysis  revealed  that  restenosis  leading  to
AP  was  suppressed  by  statin  treatment  (Fig.  4).  Although
e  novo  lesions  (both  target  vessel  and  non-target  vessel)
nt  curves  of  the  primary  endpoint.
212  
Figure  3  Hazard  ratio  for  the  composite  endpoint  events  and
for each  endpoint  event.  CHF,  congestive  heart  failure;  CI,  con-
ﬁdence interval;  CV,  cardiovascular;  MI,  myocardial  infarction;
rAP, recurrent  angina  pectoris  requiring  emergency  rehospital-
ization.





















































mI, conﬁdence  interval;  rAP,  recurrent  angina  pectoris  requiring
mergency  rehospitalization.
esponsible  for  rAP  tended  to  be  reduced  by  statin  treat-
ent  (Table  2),  there  was  no  signiﬁcant  difference  between
he  two  groups  (Fig.  5).
iscussionhe  present  study  showed  that  discretional  statin  use
ecreases  the  incidence  of  cardiovascular  events  after  PCI  in
apanese  patients  with  normal  cholesterol  levels.  Patients




Table  2  Coronary  angiography  ﬁndings  in  the  rAP  cases.
Outcome,  n Statin  group  (n  =  482) Non-s
rAP  total  23  51  
Restenosis 13  29  
New lesion  8  18  
Target vessel  origin 1  2  
Non-target vessel  origin 7 16  
Unknown 2  4  
CI, conﬁdence interval; rAP, recurrent angina pectoris requiring emergR.  Tsunoda  et  al.
odest  doses.  There  was  a 5.2%  absolute  and  a 34%  relative
isk  reduction  in  the  primary  combined  endpoint.  Although
he  rate  of  coronary  stent  implantation  in  our  study  was
igher  than  that  in  the  LIPS  study,  the  effect  of  statins
n  cardiovascular  events  after  PCI  was  similar  comparing
ur  results  with  the  LIPS  trial.  Of  all  the  primary  endpoint
vents,  the  occurrence  of  rAP  showed  the  most  signiﬁcant
eduction  in  response  to  statins.  In  contrast,  hard  endpoint
vents,  such  as  cardiovascular  death  and  MI,  were  not  inﬂu-
nced  by  statin  treatment.  These  results  are  comparable
ith  the  results  observed  in  the  LIPS  trial  [5].  One  rea-
on  why  hard  endpoint  events  such  as  cardiovascular  death
nd  non-fatal  MI  occurred  equally  in  the  two  groups  could
epend  on  our  manner  of  follow-up  after  PCI.  Most  Japanese
atients  undergo  routine  CAG  6—9  months  after  the  indexed
rocedure  regardless  of  the  presence  of  ischemic  symptoms.
ince  there  is  signiﬁcant  restenosis  after  implantation  of
are  metal  stents  [9],  routine  CAG  followed  by  provisional
epeat  PCI  might  be  effective  in  the  prevention  of  future
vents  in  patients  with  silent  but  signiﬁcant  myocardial
schemia.
Nakamura  et  al.  [10]  reported  that  all-cause  death  but
ot  cardiac  death  was  reduced  by  statin  therapy  in  PCI
atients.  However,  the  reported  magnitude  of  reduction
ay  have  been  overestimated  as  Zhang  suggested  [11].
herefore,  further  studies  are  needed  to  elucidate  the  mor-
ality  beneﬁt  of  statins  in  patients  undergoing  PCI.
In  the  present  study,  most  of  the  culprit  lesions  respon-
ible  for  rAP  were  identiﬁed  by  emergent  CAG.  This  is
he  strength  of  our  study  as  compared  with  other  studies.
AG  revealed  that  statin  treatment  signiﬁcantly  reduced
estenosis  of  target  lesions  rather  than  the  development  of
ew  lesions  that  caused  rAP.  Although  Kaplan—Meier  analysis
f  new  lesions  (including  target  vessel  and  non-target  vessel)
howed  that  the  cumulative  event  curves  seemed  to  sepa-
ate  gradually  starting  3  moths  after  statin  treatment,  our
tudy  was  not  powered  to  detect  signiﬁcant  differences  in
he  location  and  type  of  lesion  responsible  for  rAP.  Recently,
he  PCI-PROVE  IT  study  reported  that  intensive  statin  ther-
py  reduced  not  only  target  vessel  revascularization  but
lso  non-target  vessel  revascularization  in  patients  treated
ith  PCI  for  acute  coronary  syndrome  (ACS)  [12]. That  study
nrolled  almost  3  times  more  patients  than  our  study,  and
he  patients  were  randomly  assigned  to  either  intensive  or
odest  statin  therapy.  The  mean  LDL-C  levels  with  intensivetatin  therapy  declined  from  107  to  56.5  mg/dl  at  a  mean
ollow-up  of  24  months.  If  our  statin  group  had  a  reduction
n  LDL-C  levels  that  was  similar  to  the  reduction  achieved  by
tatin  group  (n  =  497)  Hazard  ratio  (95%  CI)  p-Value
0.47  (0.29—0.77)  0.0027
0.47  (0.24—0.90)  0.0236
0.46  (0.20—1.07)  0.07
0.52  (0.05—5.69)  0.589
0.46  (0.19—1.10)  0.0835
—  —
ency rehospitalization.























iFigure  5  Kaplan—Meier  event  curves  for  restenosis  (upper  pa
angina pectoris  requiring  emergency  rehospitalization.
intensive  statin  therapy  in  PCI-PROVE  IT,  then  it  is  possible
that  new  lesions  causing  rAP  might  have  been  signiﬁcantly
reduced  by  statin  treatment  in  our  study.
In  addition  to  the  effects  of  statins  on  coronary  spasm
[13], the  so-called  pleiotropic  effects  of  statins,  such  as  anti-
inﬂammatory  [14], anti-oxidative  [15], and  anti-thrombotic
[16]  effects  and  improvement  in  endothelial  function  [17]
may  have  played  an  important  role  in  the  prevention  of  rAP.
Moreover,  we  previously  reported  that  pravastatin  increased
plasma  levels  of  adiponectin  and  had  anti-diabetic  effects
in  patients  with  CAD  [18,19],  and  this  could  have  reduced
the  progression  of  coronary  atherosclerosis.
In  the  MIRACL  study,  which  included  patients  with  ACS
without  ST-elevation,  statins  were  associated  with  a  lower
risk  of  rAP  [20], similar  to  the  results  of  the  present  study.
However,  cases  with  PCI  were  excluded  in  the  MIRACL  study,
and  this  is  not  consistent  with  clinical  practice  and  most
current  guidelines.  The  results  of  the  present  study  clearly
demonstrated  that  statins  reduced  the  incidence  of  rAP
during  2  years  of  follow-up,  even  after  successful  PCI.  Fur-
thermore,  unlike  the  MIRACL  study,  CAG  was  performed  in
our  study  to  elucidate  the  precise  mechanism  responsible
for  rAP.  Kaplan—Meier  analysis  of  rAP  in  the  present  study
revealed  that  the  cumulative  event  curves  began  to  sepa-
rate  3  months  after  the  initiation  of  statin  therapy.  This  is
somewhat  similar  to  the  results  of  the  MIRACL  study,  in  which
a  signiﬁcant  difference  in  rAP  was  observed  after  16  weeks
of  statin  treatment.  When  the  patients  in  the  present  study
were  stratiﬁed  according  to  the  culprit  lesion  responsible  for
rAP,  it  appeared  that  both  new  lesions  and  restenosis  con-




oand  new  lesions  (lower  panel)  in  the  rAP  cases.  rAP,  recurrent
as  no  signiﬁcant  difference  in  number  of  patients  with
ew  lesions  causing  rAP.  The  new  lesions  emerged  from  the
eginning  of  follow-up,  whereas  restenosis  occurred  mainly
 months  after  PCI.  Based  on  these  results,  we  suggest  that
tatin  treatment  following  PCI  acts  to  prevent  rAP  by  atten-
ating  new  lesions  that  develop  during  early  follow-up,  as
ell  as  by  attenuating  late  restenosis.
Recently,  Nishigaki  et  al.  [21]  reported  that  PCI  with  med-
cal  therapy  reduced  deaths  and  ACS  events  in  Japanese
atients  with  stable,  low-risk  CAD.  However,  statins  were
sed  in  only  half  of  their  study  patients,  and  the  mean  LDL-C
evel  was  >100  mg/dl.  More  extensive  use  of  statins  after  PCI
ay  contribute  to  the  prevention  of  recurrent  symptomatic
yocardial  ischemia  requiring  emergent  rehospitalization.
With  the  introduction  of  DES,  the  rates  of  restenosis  and
arget-vessel  revascularization  have  dropped  below  10%.
owever,  angioscopy  showed  that  the  restenosis  site  in
atients  treated  with  DES  looked  like  vulnerable  plaque  [22].
herefore,  statins  could  still  be  useful  after  PCI  even  in
atients  treated  with  DES.
tudy  limitations
ur  study  has  several  limitations.  The  most  important  limi-
ation  was  the  heterogeneity  of  the  study  population  since  it
ncluded  ST-elevation  MI,  non-ST-elevation  MI/uAP,  and  sta-
le  angina  patients;  and  all  patients  were  treated  by  either
onventional  balloon  angioplasty  or  stenting.  The  effect  of
tatins  would  be  different  between  acute  and  chronic  CAD
























ngioplasty.  However,  we  could  not  compare  the  differ-
nces  in  the  effect  of  statins  among  subgroups  because
f  the  small  number  of  patients  in  this  study,  especially
atients  treated  by  conventional  balloon  angioplasty.  Sec-
nd,  although  statins  reduced  only  restenosis  causing  rAP,
e  could  not  precisely  assess  the  mechanisms  responsible
or  this  effect.
onclusions
iscretional  statin  treatment  with  relatively  low  doses
educes  the  incidence  of  cardiovascular  events  after  PCI
n  Japanese  patients  with  normal  cholesterol  levels.  The
eduction  in  events  appears  to  be  mainly  due  to  a  reduc-
ion  in  the  incidence  of  rAP  that  is  caused  by  restenosis  of
he  target  lesion.
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ppendix A.
he  MUSASHI  investigators  are  listed  below  in  alphabetical
rder  by  center.
Amakusa  Medical  Center:  Naritsugu  Sakaino,  Shota  Naka-
mura,  Shinichi  Nakamura;  Arao  City  Hospital:  Ikuo  Misumi;
Asahikawa  Medical  College  Hospital:  Naoyuki  Hasebe,
Masaru  Yamaki,  Kenjiro  Kikuchi;  Chikamori  Hospital:
Naohisa  Hamashige;  Dokkyo  University  Koshigaya  Hos-
pital:  Toshihiko  Uchida,  Hiroshi  Takayanagi;  Fukuoka
Tokushukai  Medical  Center:  Hideki  Shimomura,  Kenichi
Tsujita,  Takuro  Yamashita;  Fukuoka  University  Hospital:
Keijiro  Saku;  Gunma  Prefectural  Cardiovascular  Center:
Shigeru  Ohshima;  Health  Insurance  Hitoyoshi  General  Hos-
pital:  Kenji  Obata,  Hideki  Oka;  Hirosaki  University  Hospital:
Ken  Okumura,  Toshiro  Matsunaga;  Hiroshima  City  Hos-
pital:  Masaharu  Ishihara;  Izumi  City  Hospital:  Shigenobu
Tateishi;  Japanese  Red  Cross  Kumamoto  Hospital:  Hitoshi
Sumida,  Ryusuke  Tsunoda,  Yasuhiro  Ogata;  Kagoshima  City
Hospital:  Hitoshi  Toda;  Kagoshima  Medical  Association
Hospital:  Hiroyuki  Torii;  Kagoshima  University  Hospital:
Chuwa  Tei;  Karatsu  Red  Cross  Hospital:  Takanobu  Nii;
Kihara  Cardiovascular  Clinic:  Hajime  Kihara;  Kitasato  Uni-
versity  Hospital:  Naoto  Fukuda,  Tohru  Izumi;  Kohseikai
Hospital:  Yoshihiro  Iwasaki;  Kumamoto  Central  Hospital:
Shuichi  Oshima;  Kumamoto  City  Hospital:  Yoshihiro  Kimura;
Kumamoto  Kinoh  Hospital:  Yuji  Mizuno;  Kumamoto  Regional
Medical  Center:  Nobutaka  Hirai;  Kumamoto  Rosai  Hospi-
tal:  Toshiyuki  Matsumura,  Hideki  Doi;  Kumamoto  University
Hospital:  Hisao  Ogawa,  Tomohiro  Sakamoto,  Sunao  Kojima,
Koichi  Kaikita;  Mie  University  Hospital:  Takeshi  Nakano,
Naoki  Isaka;  Minamata  City  General  Hospital  and  Medi-
cal  Center:  Hideki  Maruyama;  Miyazaki  Medical  Association
Hospital:  Yoshisato  Shibata;  Miyazaki  University  Hospi-
tal:  Takuro  Imamura,  Tanenao  Eto;  Miyazaki  PrefecturalR.  Tsunoda  et  al.
Nobeoka  Hospital:  Yasushi  Moriyama,  Nobuyasu  Yamamoto;
Nagasaki  Municipal  Medical  Center:  Kazuaki  Yakabe;
Nagasaki  University  Hospital  2nd  Internal  Medicine:
Yoshiyuki  Miyahara,  Shigeru  Kohno;  Nagasaki  University
Hospital  3rd  Internal  Medicine:  Katsusuke  Yano,  Yuji  Koide;
Nara  Medical  University  Hospital:  Yoshihiko  Saito,  Shiro
Uemura;  National  Hospital  Organization  Kumamoto  Medical
Center:  Kazuteru  Fujimoto,  Yuji  Miyao;  National  Hospital
Organization  Kyushu  Cardiovascular  Center:  Tatsuru  Mat-
suoka;  National  Hospital  Organization  Oita  Medical  Center:
Tatsuhiko  Ooie;  Oji  General  Hospital:  Hitoshi  Ooiwa;  Oki-
tama  Public  General  Hospital:  Motoyuki  Matsui;  Saiseikai
Kumamoto  Hospital:  Takashi  Honda,  Koichi  Nakao;  Saitama
Medical  Center:  Nobuo  Yoshimoto;  Sapporo  Medical  Univer-
sity  Hospital:  Kazufumi  Tsuchihashi,  Kazuaki  Shimamoto;
Sasebo  City  General  Hospital:  Toshihiko  Yamasa;  Shinbeppu
Hospital:  Natsuki  Nakamura;  Social  Insurance  Ohmuta-
Tenryoh  Hospital:  Kohshi  Matsuyama;  Social  Insurance
Yatsushiro  General  Hospital:  Toshifumi  Tabuchi;  Tamana
Chuo  Municipal  Hospital:  Toru  Takahashi;  Tenyoukai  Chuo
Hospital:  Akihiro  Miyamura;  University  of  the  Ryukyus  Hos-
pital:  Michio  Shimabukuro;  Urasoe  General  Hospital:  Toru
Higa;  Yamagata  University  Hospital:  Isao  Kubota;  Yokohama
City  Medical  Center:  Kiyoshi  Hibi,  Masami  Kosuge,  Kazuo
Kimura.
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